MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
May 29, 2020

Canopy Growth (CGC, $17.23) reports wider-than-expected loss for fiscal Q4

Canopy Growth reported a wider-than-anticipated loss for its fiscal fourth quarter.

The cannabis company’s  net loss for the quarter came in at - C$3.72 a share, compared to the -44 cents a share loss expected by analysts polled by FactSet. The loss included C$743 million in impairment and restructuring charges, most of which are non-cash. The year-ago quarter’s loss was -C$1.10 a share.

However, sales increased to C$115.1 million (from the year-ago quarter’s C$106.5 million).

Due to the coronavirus pandemic, Canopy is withdrawing its prior guidance for positive adjusted EBITDA and net income.

Tickeron's A.I.-powered scorecard rates Canopy Growth a STRONG BUY.

Current price $17.18 crossed the support line at $17.64 and is trading between $17.64 support and $15.10 support lines. Throughout the month of 04/27/20 - 05/28/20, the price experienced a +24% Uptrend. During the week of 05/20/20 - 05/28/20, the stock enjoyed a +28% Uptrend growth.

Bullish Trend Analysis

The Momentum Indicator exceeded the 0 level on May 15, 2020. Traders may consider buying the ticker or exploring call options. In 67 of 87 cases where the ticker's Momentum Indicator exceeded 0, its price rose further within the subsequent month. The odds of a continued Uptrend are 77%.

The Moving Average Convergence Divergence (MACD) just turned positive. Considering data from situations where CGC's MACD histogram became positive, in 37 of 45 cases, the price rose further within the following month. The odds of a continued Uptrend are 82%.

The 10-day Moving Average for this ticker crossed above its 50-day Moving Average on April 28, 2020, which can be construed as a buy signal, indicating that the trend is shifting higher. In 10 of 13 similar cases where CGC's 10-day Moving Average crossed above its 50-day Moving Average, the price rose further within the following month. The odds of a continued Uptrend are 77%.

The Aroon Indicator entered an Uptrend today. In 172 of 228 similar cases where CGC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 29 of 42 cases where CGC's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 69%.

Fundamental Analysis (Ratings)

Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 72%. During the last month, the daily ratio of advancing to declining volumes was 1.99 to 1.

The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CGC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.87) is normal, around the industry mean (1.09). P/E Ratio (0.00) is within average values for comparable stocks, (30.33). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (115.92). Dividend Yield (0.00) settles around the average of (1.05) among similar stocks. P/S Ratio (25.30) is also within normal values, averaging (11.24).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Related Ticker: CGC

Momentum Indicator for CGC turns negative, indicating new downward trend

CGC saw its Momentum Indicator move below the 0 level on October 21, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In of the 75 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CGC turned negative on October 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

CGC moved below its 50-day moving average on October 16, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CGC crossed bearishly below the 50-day moving average on October 21, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CGC broke above its upper Bollinger Band on October 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CGC entered a downward trend on October 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.182) is normal, around the industry mean (17.223). P/E Ratio (0.000) is within average values for comparable stocks, (72.893). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.088). CGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.909) is also within normal values, averaging (48.047).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), BioCryst Pharmaceuticals (NASDAQ:BCRX), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.02B. The market cap for tickers in the group ranges from 2.12K to 65.2B. ZTS holds the highest valuation in this group at 65.2B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 42%. HYEX experienced the highest price growth at 74%, while MILFF experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -9%. For the same stocks of the Industry, the average monthly volume growth was 70% and the average quarterly volume growth was 61%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 55
SMR Rating: 82
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
Related Portfolios: FARMING INDUSTRY
View a ticker or compare two or three
CGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CGC showed earnings on August 08, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a producer of medical marijuana

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Agricultural Commodities Or Milling
Address
1 Hershey Drive
Phone
+1 855 558-9333
Employees
1621
Web
https://www.canopygrowth.com
Interact to see
Advertisement
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
#investment#trading
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
#investment#trading
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading
Wall Street expects strong profit growth from the Magnificent Seven tech giants in 2025. Discover how to trade Apple, Microsoft, Amazon, Nvidia, Tesla, Meta, and Alphabet using AI-powered Double Agent strategies and smart hedging with inverse ETFs like QID.
On May 2, 2025, a diverse group of companies across energy, financial services, basic materials, consumer discretionary, and healthcare will release their Q1 2025 earnings.
In April 2025, five tech giants—NVIDIA, Tesla, Meta, Palantir, and Amazon—each surged over 40%, driven by AI breakthroughs, strong earnings, and market momentum. Discover what fueled the rally and how Tickeron’s AI trading bots helped investors outperform even these star stocks.
#investment
Markets ended April with mixed signals—gold slid on trade optimism, Big Tech lifted the Nasdaq, and Bitcoin steadied near $94K. With U.S. GDP contracting and job growth beating forecasts, investors brace for more volatility amid tariffs and central bank moves.
As Warren Buffett announces his retirement, investors turn to his trusted Buffett Indicator—a ratio of market cap to GDP—as a key gauge of market valuation.
#investment
Markets move in repeating cycles—Accumulation, Uptrend, Distribution, and Downtrend. Learn how to recognize each phase and deploy Tickeron’s AI-powered Double Agent strategy to adapt, protect capital, and profit in any market condition.
#trading
Discover how confirmation trading techniques—like moving average crossovers and volume-backed breakouts—can improve accuracy and reduce false signals. Learn how Tickeron’s AI automates these strategies for smarter, faster, and more disciplined trading.
#trading
Hedge funds are ramping up bearish bets on small-cap stocks, with Russell 2000 short interest hitting new highs. As macro headwinds mount and technical support teeters, Tickeron’s AI Double Agents step in to navigate the looming sell-off with precision.
#investment#trading#artificial_intelligence
SPY’s Momentum Indicator turned bullish on April 25, 2025, signaling a potential trend shift with a 90% historical success rate. This article explores how economic scarcity, technical signals, and AI-driven tools like Tickeron’s A.I.dvisor shape investor decisions in volatile markets.
#trading
On May 7, 2025, NVIDIA gained 3.1% on bullish AI momentum and strong data center demand, while Alphabet plunged over 7% amid regulatory fears and growing AI competition—highlighting the tech sector's diverging fortunes in a volatile market.
#investment
A volatile week in financial markets saw the S&P 500 pull back after a record streak, gold surge nearly 5% on Fed jitters, and Bitcoin soar past $104K on trade deal hopes—highlighting the growing impact of policy decisions, earnings, and geopolitical sentiment on asset prices.
ickeron’s AI-powered prediction that Bitcoin would reach $109,000 is nearing reality, as BTC climbs to $103,000. This article explores the accuracy of the forecast, the market forces behind the rally, and how traders can leverage AI tools like Double Agents to stay ahead.
#trading#investment
Monero (XMR) has flashed a bullish signal as its 10-day moving average crosses above the 50-day, historically marking the start of uptrends. With renewed focus on digital privacy and support from Tickeron’s AI agents, XMR may be poised for a quiet breakout.
Tech giants Microsoft, Oracle, Meta, Amazon, and Alphabet (MOMAA) are set to invest a record $320B in AI and cloud infrastructure in 2025—a bold move that could reshape the digital economy. This article explores what’s driving the surge and how investors can respond.
Tickeron’s AI has detected a Rectangle Bottom Bullish pattern in Starbucks (SBUX), signaling a potential short-term rally. With a breakout price of $84.77 and a 63% confidence level, traders are watching closely as AI-driven insights point to a possible upward trend.
#trading
Cisco Systems is set to release its Q3 2025 earnings on May 14, with analysts expecting $0.91 EPS and $14.05B in revenue. This report will test Cisco’s strength in AI and cybersecurity amid networking headwinds. Can Tickeron’s AI Double Agent predict the market reaction?
#investment